Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial

Lancet

Volumn 357, Issue 9272, 2001, Pages 1905-1914

  Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME;

EID: 0035897888     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05059-5     Document Type: Article

References (23)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2
3. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
4. An international, multicenter, randomized comparison of reteplase with alteplase for acute myocardial infarction
5. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
6. Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction
7. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial
8. INTRO AMI: Marked enhancement of arterial patency with eptifibatide and low-dose t-PA in acute myocardial infarction
9. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (The EPIC Trial)
10. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: An analysis of outcomes and treatment choices in the GUSTO I and ASSENT 2 studies
11. Statistical methods for comparison to placebo in active-control trials
12. Discrete sequential boundaries for clinical trials
13. The illusion of reperfusion: Does anyone achieve optimal myocardial reperfusion?
14. Recurrent ischemia after thrombolysis for acute myocardial infarction
15. Frontiers in interventional cardiology
16. Towards a new frontier in myocardial reperfusion therapy
17. An alternative to the use of two-sided tests in clinical trials
18. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
19. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
20. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
21. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
22. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization
23. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention